Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.31 |
| ▸ | GABRE | P78334 | 2/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.31 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL18241091 | 0.84 | OPRM1 (0.39) | OPRM1ALDH1A1 | |
| SCHEMBL6547441 | 0.82 | — | — | |
| SCHEMBL28659791 | 0.82 | OPRM1 (0.34) | OPRM1 | |
| SCHEMBL27868439 | 0.81 | — | — | |
| SCHEMBL2550870 | 0.80 | OPRM1 (0.33) | OPRM1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3823013 | 0.79 | — | — | |
| SCHEMBL28102817 | 0.78 | — | — | |
| SCHEMBL232865 | 0.78 | OPRM1 (0.37) | OPRM1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1845045 | 0.78 | — | — | |
| SCHEMBL27656994 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112313317-A | Purification of edible oils and fats with amino-functionalized silica adsorbent materials | 美国达拉斯集团公司 | 2021-02-02 | — | — | CN | claimed |
| US-12570899-B2 | Bright silver based quaternary nanostructures | SHOEI CHEMICAL INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-20240263069-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | SHOEI CHEMICAL INC. (JP) | 2024-08-08 | — | — | US | disclosed |
| US-11970646-B2 | Bright silver based quaternary nanostructures | SHOEI CHEMICAL INC. (JP) | 2024-04-30 | — | — | US | disclosed |
| EP-3816247-B1 | CURING MIXTURE | EVONIK OPERATIONS GMBH (DE) | 2022-12-07 | — | — | EP | disclosed |
| US-20220228057-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | NANOSYS, INC. (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3973033-A1 | BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES | Nanosys, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11254819-B2 | Curing agent mixture | EVONIK OPERATIONS GMBH (DE) | 2022-02-22 | — | — | US | disclosed |
| EP-2994495-B2 | CROSSLINKING OF IPMS ADDUCTS AND AMINOSILANES | EVONIK OPERATIONS GMBH (DE) | 2021-09-22 | — | — | EP | disclosed |
| EP-3816247-A1 | CURING MIXTURE | Evonik Operations GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-6156468-A | Blocking layer with light scattering particles having rough surface | XEROX CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-6096464-A | CHARGE TRANSPORT LAYER INCLUDES A CHARGE TRANSPORT MATERIAL AND A ROTAXANE MATERIAL; PHOTORECEPTORS HAVE EXCELLENT XEROGRAPHIC PROPERTIES SUCH AS HIGH PHOTOSENSITIVITY AND LOW RESIDUAL VOLTAGE AND IMPROVED ABRASION RESISTANCE | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-6071661-A | Imaging member containing branched polycarbonate | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| US-5846681-A | Multilayer imaging member having improved substrate | XEROX CORPORATION (US) | 1998-12-08 | — | — | US | disclosed |
| US-5830613-A | Electrophotographic imaging member having laminated layers | XEROX CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0798346-A2 | Hydroxygallium phthalocyanine and alkoxygallium phthalocyanine dimers | XEROX CORPORATION (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0742269-A1 | Halogenindium phthalocyanine crystals | XEROX CORPORATION (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5529870-A | Halogenindium phthalocyanine crystals | XEROX CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5422213-A | Multilayer electrophotographic imaging member having cross-linked adhesive layer | XEROX CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0585675-A1 | Multi-layer electrophotographic imaging member having cross-linked adhesive layer | XEROX CORPORATION (US) | 1994-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570899-B2 | Bright silver based quaternary nanostructures | LGALS3, ANXA3, ATXN2L | OPRM1 2012/4885GABRP 3550/4885GABRD 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.